The Pharma Data

APRIL 15, 2022

The top protein neutralized the virus with similar or greater potency than antibody treatments with Emergency Use Authorization status from the U.S. Notably, the top protein also neutralized all tested SARS-CoV-2 variants, something that many clinical antibodies have failed to do. Food and Drug Administration (FDA).

Antibody 52

Antibody Protein Engineer Manufacturing 52

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

The Pharma Data

NOVEMBER 30, 2020

About NVX-CoV2373 NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. In preclinical studies, NVX-CoV2373 induced antibodies that block binding of spike protein to cellular receptors and provided protection from infection and disease.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

Drug Discovery World

APRIL 12, 2024

The Food and Drug Administration (FDA) has cautioned that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. This latest approval means that Enhertu now has five approved indications, including for breast cancer. In DESTINY-Lung01, ORR of 52.9%

Antibody 52

Antibody Clinical Trials Clinical Trials Trials 52

Drug Discovery World

JULY 3, 2023

This covered features of the TME which are hostile to CAR T cell efficacy, strategies for engineering CARs to address the solid tumour TME hurdles, as well as combination treatments with novel CARs such as chemotherapy, radiotherapy, and oncolytic virus.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

Drug Discovery World

NOVEMBER 9, 2023

DDW Editor Reece Armstrong speaks to Christian Leisner , Chief Executive Officer of antibody therapeutics’ developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: What kind of T-cell response can we expect from the MHC-targeting antibody fragment-based approach?

Antibody 64

Antibody Protein Development Engineer 64

The Pharma Data

MAY 27, 2022

Roche today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from 3-7 June and the European Hematology Association (EHA) 2022 Congress from 9-12 June.

Antibody 52

Antibody In-Vitro Medicine Engineer 52

The Pharma Data

DECEMBER 13, 2020

Up to 1% of all solid tumors harbor NRG1 fusions, therefore, it is important to identify this patient population and develop therapies that can treat them. [1]. HMBD-001 is a uniquely differentiated anti-HER3 neutralizing antibody that was developed using Hummingbird’s proprietary Rational Antibody Discovery platform.

Clinical Development 52

Clinical Development Medicine Development Antibody 52

Pharmaceutical Technology

MARCH 23, 2023

Seagen specialises in developing antibody-drug conjugates (ADCs) which will complement Pfizer’s oncology portfolio. Seagen will maintain its operations in the Seattle area and will leverage Pfizer’s protein-engineering capabilities to develop next-generation biologics.

Licensing 147

Licensing Licensing Sales Trials 147

Pharmaceutical Technology

FEBRUARY 18, 2023

Gevokizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase I program in Metastatic Renal Cell Carcinoma. According to Globaldata, it is involved in 34 clinical trials, of which 20 were completed, 1 is ongoing, and 13 were terminated.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

Drug Discovery World

MAY 25, 2023

It is accessible, boosts developer productivity and aims to save up to 80% of the time and cost associated with traditional API management strategies.

Production 52

Production Reagent DNA Drugs 52

Drug Discovery World

FEBRUARY 28, 2024

Using IgE to treat cancer In the UK, a Cancer Research UK-funded clinical trial has shown, for the first time, that a new class of antibody could benefit cancer patients whose existing treatments have stopped working. Currently, all antibodies approved for the treatment of cancer belong to a class known as IgG.

Development 64

Development Research Drugs Antibody 64

pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 101

RNA Genetics Dermatology Antibody 101

pharmaphorum

NOVEMBER 19, 2021

The three assets are a pair of anti-TIGIT antibodies – domvanalimab (AB154) and AB308 – along with adenosine A2a/A2b receptor antagonist etrumadenant and small-molecule CD73 inhibitor quemliclustat. Gilead has already snapped up rights to PD-1 inhibitor zimberelimab (AB122), another clinical-stage candidate covered by the alliance.

Drugs 52

Drugs Antibody Engineer Development 52

The Pharma Data

JANUARY 13, 2021

The patent application is titled “Anti-CD154 Antibodies and Uses Thereof” and published under International Publication No. TNX-1500 is a third generation anti-CD40-ligand mAb that has been designed by protein engineering to decrease Fc?RII WO 2021/001458 A1. Tonix’s President and Chief Executive Officer, Seth Lederman, M.D.

Antibody 52

Antibody Development Protein Vaccination 52

XTalks

FEBRUARY 24, 2023

Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that works by targeting the protein CD20 on the surface of B cells and CD3 on the surface of T cells. Dr. Laport: Lunsumio (mosunetuzumab-axgb) is the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA.

FDA Approval 52

FDA Approval Drugs Antibody Medicine 52

The Pharma Data

OCTOBER 27, 2020

Clynes established the critical role of Fc receptor engagement underlying the efficacy of antitumor antibodies, providing the road map for the development of a new class of potency enhanced Fc engineered antibodies in cancer, including anti-CD20, anti-CD19 and anti-HER2 antibodies (obinutuzumab, tafacitamab, margetuximab).

Antibody 52

Antibody Genetic Engineering Engineer Development 52

pharmaphorum

JANUARY 4, 2023

The University of Michigan spinoff’s NanoDisc technology relies on the use of synthetic, high-density lipoproteins that can be engineered to carry a payload of antigens, presenting them for recognition by the immune system – specifically, dendritic cells within lymph nodes.

Immune Response 52

Immune Response Engineer Licensing Licensing 52

The Pharma Data

OCTOBER 26, 2020

On 14 May 2018, the Company announced a collaboration with GlobalCo to work on its CDX antibody. This work complements the Company’s own development work currently being undertaken. This additional extension of the collaboration will allow us to choose the best CDX antibody for pre-clinical and clinical development.”

Development 40

Development Antibody Engineer Production 40

The Pharma Data

DECEMBER 13, 2020

Margetuximab is an investigational, Fc-engineered, monoclonal antibody targeting HER2. About 15 to 20% of breast cancers cases are HER2+, and antibody-based therapies targeting HER2 have significantly improved outcomes of patients with HER2+ breast cancer. Zai Lab is leading clinical development in its territory. “We

Antibody 52

Antibody Clinical Trials Clinical Trials Licensing 52

Drug Discovery World

FEBRUARY 12, 2024

In 2024, we can expect another wave of innovative new drugs to be developed using the technology, given that the AI-fuelled small molecule discovery pipeline is growing by almost 40% annually.” Developability prediction is often used in antibody development to reduce wet lab experiments and accelerate the drug discovery process.

Genome 139

Genome Genomics Life Science Gene Therapy 139

The Pharma Data

NOVEMBER 9, 2020

(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the U.S. Currently in late-phase clinical development, NVXCoV2373 is a stable, prefusion protein made using Novavax’ nanoparticle technology and includes its proprietary MatrixM adjuvant.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 8, 2020

Since partnering with Eli Lilly to produce the first monoclonal antibody therapy approved for mild-to-moderate COVID-19 patients, antibody discovery company AbCellera is going big on the Nasdaq. Tackle the toughest problems in drug development.” The promise to partners is to “move quickly. Reduce cost. Nuance Pharma .

RNA 52

RNA Antibody Life Science Protein 52

The Pharma Data

JUNE 7, 2023

Results will be presented on June 6 during an oral presentation (#9004) at the American Society of Clinical Oncology Annual Meeting (#ASCO23). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN).

Trials 40

Trials Antibody Development Genome 40

The Pharma Data

DECEMBER 13, 2020

Nasdaq: SYBX ), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 has advanced into the combination therapy stage of the ongoing Phase 1 trial. CAMBRIDGE, Mass. , 14, 2020 /PRNewswire/ — Synlogic, Inc. Sokolovska, A., Nature Communications 11, 2739 (2020)).

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

The Pharma Data

DECEMBER 17, 2020

Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs.

Development 52

Development Gene Therapy Engineer Life Science 52

The Pharma Data

OCTOBER 21, 2020

T cell therapies by Adicet, and marks the beginning of clinical development of a deep pipeline of “off-the-shelf” ?? We are particularly excited to advance on our goal to exploit the therapeutic potential of our first in class engineered CAR ?? T cell products,” said Chen Schor, President and Chief Executive Officer of Adicet.

Immune Response 40

Immune Response Engineer Clinical Trials Clinical Trials 40

The Pharma Data

APRIL 27, 2023

It is also an off-the-shelf therapy, meaning that people do not have to wait for cell collection and genetic engineering before starting treatment, which could be particularly important for patients who are at a high-risk of their disease progressing. A final decision is expected from the European Commission (EC) in the near future.

Genetic Engineering 40

Genetic Engineering Clinical Development Antibody Medicine 40

The Pharma Data

MAY 15, 2023

Roche’s Chief Medical Officer and Head of Global Product Development. “If If approved, this would be the third indication for Vabysmo, the first bispecific antibody available for the treatment of retinal conditions that can cause blindness.” 7 About Vabysmo® (faricimab) Vabysmo is the first bispecific antibody approved for the eye.

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

OCTOBER 26, 2020

He will address the preclinical performance of AR-711, the advantages of direct lung delivery using nebulized aerosols, and the COVID-19 clinical program. AR-711 is a fully human immunoglobulin 1, or IgG1, monoclonal antibody discovered from screening the antibody secreting B-cells of convalescent COVID-19 patients.

Antibody 52

Antibody Genetic Engineering Development Clinical Trials 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

DECEMBER 13, 2023

In the ever-evolving landscape of therapeutic development, the role of antibodies has become increasingly apparent. Antibodies are used as therapeutics, components of therapeutics such as antibody-drug conjugates (ADC) and CAR-T cells, and as companion diagnostic tools.

Life Science 59

Life Science Antibody Manufacturing In-Vivo 59

The Pharma Data

APRIL 12, 2023

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. Chief Medical Officer and Head of Global Product Development.

Antibody 40

Antibody In-Vitro Development Trials 40

The Pharma Data

DECEMBER 10, 2020

The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. ImmunityBio’s hAd5 vaccine generated robust neutralizing antibody activity that was present 14 days post-final vaccination. This press release features multimedia. Graphic: Business Wire).

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

OCTOBER 18, 2022

Basel also boasts world-class academic institutions, hosting the Department of Biosystems Science and Engineering of ETH Zurich (D-BSSE) – one of the two Swiss Federal Institutes of Technology – and the University of Basel. Engimmune develops highly potent and specific immunotherapies based on two distinct TCR cancer targeting approaches.

Life Science 52

Life Science Engineer Research Clinical Trials 52

The Pharma Data

DECEMBER 9, 2020

With the launch of Overland, we are creating a robust research and development engine in parallel with the significant growth and opportunity presented by Asia’s evolving biotech industry. Amolyt has also acquired an option to license the identified candidates for future clinical development.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52